Autocrine motility factor signaling enhances pancreatic cancer metastasis

Clinical Cancer Research

Volumn 10, Issue 22, 2004, Pages 7775-7784

  Tsutsumi, Soichi ^a   Yanagawa, Takashi ^b   Shimura, Tatsuo ^a   Kuwano, Hiroyuki ^a   Raz, Avraham ^b,c  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOCRINE MOTILITY FACTOR; CYTOKINE; GLUCOSE 6 PHOSPHATE ISOMERASE; MITOGENIC AGENT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; ZINC FINGER PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; GENE OVEREXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MODEL;

AGED; ANIMALS; ANOXIA; AUTOCRINE MOTILITY FACTOR; BLOTTING, NORTHERN; BLOTTING, WESTERN; CADHERINS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CLONING, MOLECULAR; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTORS; TISSUE DISTRIBUTION; TRANSFECTION; UMBILICAL VEINS; UP-REGULATION; ZINC FINGERS;

EID: 9344260855     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1015     Document Type: Article

References (50)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer Statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Stojadinovic A, Brooks A, Hoos A, Jaques DP, Conlon KC, Brennan MF. An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma. J Am Coll Surg 2003;196:954-64.
3. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
4. Harrison RA. The detection of hexokinase, glucosephosphate isomerase and phosphoglucomutase activities in polyacrylamide gels after electrophoresis: a novel method using immobilized glucose 6-phosphate dehydrogenase. Anal Biochem 1974;61:500-7.
5. Watanabe H, Carmi P, Hogan V, et al. Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. J Biol Chem 1991;266:13442-8.
6. Watanabe H, Takehana K, Date M, Shinozaki T, Raz A. Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res 1996;56:2960-3.
7. Chaput M, Claes V, Portetelle D, et al. The neurotrophic factor neuroleukin is 90% homologous with phosphohexose isomerase. Nature (Lond) 1988;332:454-5.
8. Shimizu K, Tani M, Watanabe H, et al. The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Lett 1999;456:295-300.
9. Tsutsumi S, Yanagawa T, Shimura T, et al. Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling. J Biol Chem 2003;278:32165-72.
10. Nakamori S, Watanabe H, Kameyama M, et al. Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence. Cancer (Phila) 1994;74:1855-62.
11. Maruyama K, Watanabe H, Shiozaki H, et al. Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma. Int J Cancer 1995;64:316-21.
12. Takanami I, Takeuchi K, Naruke M, et al. Autocrine motility factor in pulmonary adenocarcinomas: results of an immunohistochemical study. Tumour Biol 1998;19:384-9.
13. Funasaka T, Haga A, Raz A, Nagase H. Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility. Biochem Biophys Res Commun 2001;285:118-28.
14. Funasaka T, Haga A, Raz A, Nagase H. Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt-1) expression in endothelial cells. Int J Cancer 2002;101: 217-23.
15. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000;48:919-22.
16. Buchler P, Reber HA, Buchler M, et al. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 2003;26:56-64.
17. Niizeki H, Kobayashi M, Horiuchi I, et al. Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells. Br J Cancer 2002;86:1914-9.
18. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998;153:333-9.
19. Pignatelli M, Ansari TW, Gunter P, et al. Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994;174:243-8.
20. Batlle E, Sancho E, Franci C, et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000;2:84-9.
21. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
22. Poser I, Dominguez D, de Herreros AG, Varnai A, Buettner R, Bosserhoff AK. Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor snail. J Biol Chem 2001;276:24661-6.
23. Nabi IR, Watanabe H, Raz A. Identification of B16-F1 melanoma autocrine motility-like factor receptor. Cancer Res 1990;50:409-14.
24. Niinaka Y, Paku S, Haga A, Watanabe H, Raz A. Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells. Cancer Res 1998;58:2667-74.
25. Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst (Bethesda) 2002;94:1854-62.
26. Sobin LH, Fleming ID. TNM classification of malignant tumors, edition 5 (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer (Phila) 1997;80:1803-4.
27. Tsutsumi S, Hogan V, Nabi IR, Raz A. Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Res 2003;63:242-9.
28. Tomioka D, Maehara N, Kuba K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 2001;61:7518-24.
29. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998;7:25-41.
30. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003;20:237-50.
31. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
32. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;57:3126-30.
33. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
34. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Wash DC) 1996;271:350-3.
35. Shi Q, Le X, Abbruzzese JL, et al. Constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001;61:4143-54.
36. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999;5:3711-21.
37. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003;63:1138-43.
38. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000;48:919-22.
39. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002;277:23111-5.
40. Malhotra R, Brosius FC 3rd. Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes. J Biol Chem 1999;274:12567-75.
41. Warburg O. On the origin of cancer cells. Science (Wash DC) 1956;123:309-14.
42. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68-72.
43. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science (Wash D C) 1987;235:1492-5.
44. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000; 275:21797-800.
45. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993;5:806-11.
46. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 1996;56:5309-18.
47. Timar J, Trikha M, Szekeres K, et al. Autocrine motility factor signals integrin-mediated metastatic melanoma cell adhesion and invasion. Cancer Res 1996;56:1902-8.
48. Saad ED, Hoff PM. Molecular-targeted agents in pancreatic cancer. Cancer Control 2004;11:32-8.
49. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87:161-7.
50. Cohen SJ, Ho L, Ranganathan S, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003;21:1301-6.